The weight loss drug market is exploding, with new products entering the scene to compete with big names like Ozempic. It is ...

(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...

Researchers documented a six per cent to nine per cent decline in grocery spending within the first six months of the GLP-1 ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

Therapist Debby Parker tried to lose weight for years without success. Then she discovered an online weight management ...

As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.

Ozempic was originally approved to treat people with Type 2 diabetes, but demand has surged because of the drug’s weight-loss ...

Her departure comes as the snacks maker faces challenges including higher cocoa costs, inflation that has curtailed product ...